Terms: = Prostate cancer AND BCL7A, BCL7, 605, ENSG00000110987 AND Prognosis
9 results:
1. Prognostic Factors Associated With Surviving Less Than 3 Months vs Greater Than 3 Years Specific to Spine Stereotactic Body Radiotherapy and Late Adverse Events.
Zeng KL; Sahgal A; Tseng CL; Myrehaug S; Soliman H; Detsky J; Atenafu EG; Lee Y; Campbell M; Maralani P; Husain ZA
Neurosurgery; 2021 Apr; 88(5):971-979. PubMed ID: 33475723
[TBL] [Abstract] [Full Text] [Related]
2. MiR-501-3p promotes osteosarcoma cell proliferation, migration and invasion by targeting bcl7a.
Dai J; Lu L; Kang L; Zhang J
Hum Cell; 2021 Mar; 34(2):624-633. PubMed ID: 33415690
[TBL] [Abstract] [Full Text] [Related]
3. Incidence, prevalence, and outcomes of systemic malignancy with bone metastases.
Jiang W; Rixiati Y; Zhao B; Li Y; Tang C; Liu J
J Orthop Surg (Hong Kong); 2020; 28(2):2309499020915989. PubMed ID: 32634071
[TBL] [Abstract] [Full Text] [Related]
4. MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2.
Pan MZ; Song YL; Gao F
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8795-8805. PubMed ID: 31696466
[TBL] [Abstract] [Full Text] [Related]
5. Aggressive cancer Behavior of Latent Gleason Pattern 5 in prostatectomy Specimens.
Fujimura T; Fukuhara H; Yamada Y; Taguchi S; Sugihara T; Niimi A; Nakamura M; Nakagawa T; Igawa Y; Homma Y; Kume H
Anticancer Res; 2018 Nov; 38(11):6529-6535. PubMed ID: 30396982
[TBL] [Abstract] [Full Text] [Related]
6. Circulating microRNA signature for the diagnosis of very high-risk prostate cancer.
Alhasan AH; Scott AW; Wu JJ; Feng G; Meeks JJ; Thaxton CS; Mirkin CA
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10655-60. PubMed ID: 27601638
[TBL] [Abstract] [Full Text] [Related]
7. Methylation markers for prostate cancer prognosis: a systematic review.
Chao C; Chi M; Preciado M; Black MH
Cancer Causes Control; 2013 Sep; 24(9):1615-41. PubMed ID: 23797237
[TBL] [Abstract] [Full Text] [Related]
8. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Weiss G; Cottrell S; Distler J; Schatz P; Kristiansen G; Ittmann M; Haefliger C; Lesche R; Hartmann A; Corman J; Wheeler T
J Urol; 2009 Apr; 181(4):1678-85. PubMed ID: 19233404
[TBL] [Abstract] [Full Text] [Related]
9. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract] [Full Text] [Related]
